Equities analysts predict that T2 Biosystems Inc (NASDAQ:TTOO) will report ($0.42) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for T2 Biosystems’ earnings. The lowest EPS estimate is ($0.45) and the highest is ($0.39). T2 Biosystems posted earnings of ($0.47) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 10.6%. The firm is expected to report its next earnings report on Thursday, February 15th.

According to Zacks, analysts expect that T2 Biosystems will report full-year earnings of ($1.85) per share for the current year, with EPS estimates ranging from ($1.88) to ($1.81). For the next year, analysts forecast that the company will post earnings of ($1.65) per share, with EPS estimates ranging from ($1.87) to ($1.53). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that that provide coverage for T2 Biosystems.

T2 Biosystems (NASDAQ:TTOO) last issued its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.04. T2 Biosystems had a negative return on equity of 244.82% and a negative net margin of 1,497.70%. The business had revenue of $1.11 million during the quarter, compared to the consensus estimate of $1.10 million. The company’s quarterly revenue was up 2.8% on a year-over-year basis.

Several research analysts have commented on TTOO shares. Zacks Investment Research upgraded T2 Biosystems from a “sell” rating to a “hold” rating in a research note on Thursday, October 5th. HC Wainwright began coverage on T2 Biosystems in a research note on Wednesday, October 18th. They issued a “buy” rating and a $8.00 target price for the company. Finally, Canaccord Genuity reiterated a “buy” rating and set a $6.00 price target on shares of T2 Biosystems in a research report on Monday, October 30th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $6.54.

T2 Biosystems (NASDAQ:TTOO) opened at $5.12 on Friday. T2 Biosystems has a 12 month low of $2.50 and a 12 month high of $6.99. The company has a quick ratio of 5.28, a current ratio of 5.40 and a debt-to-equity ratio of 2.25. The company has a market capitalization of $183.42, a PE ratio of -2.68 and a beta of 1.48.

Institutional investors and hedge funds have recently modified their holdings of the company. Gagnon Securities LLC bought a new stake in shares of T2 Biosystems during the 3rd quarter valued at about $396,000. Lagoda Investment Management L.P. boosted its position in shares of T2 Biosystems by 61.4% during the 3rd quarter. Lagoda Investment Management L.P. now owns 3,188,539 shares of the medical equipment provider’s stock valued at $13,392,000 after acquiring an additional 1,212,618 shares during the last quarter. Senvest Management LLC boosted its position in shares of T2 Biosystems by 17.6% during the 3rd quarter. Senvest Management LLC now owns 3,337,946 shares of the medical equipment provider’s stock valued at $14,019,000 after acquiring an additional 500,000 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of T2 Biosystems during the 3rd quarter valued at about $630,000. Finally, Susquehanna International Group LLP boosted its position in shares of T2 Biosystems by 931.3% during the 2nd quarter. Susquehanna International Group LLP now owns 85,620 shares of the medical equipment provider’s stock valued at $275,000 after acquiring an additional 95,920 shares during the last quarter. Hedge funds and other institutional investors own 59.73% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/01/19/0-42-eps-expected-for-t2-biosystems-inc-ttoo-this-quarter.html.

T2 Biosystems Company Profile

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

Get a free copy of the Zacks research report on T2 Biosystems (TTOO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.